Clinical Trial Update: STEPS Trial - Spheramine Safety and Efficacy Study [Phase 2]

View source ↗

Summary

Phase 2 STEPS trial evaluating Spheramine for Parkinson disease has been terminated; the sponsor Bayer has announced the termination of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Spheramine

Snippet

Sponsor: Bayer | Conditions: Parkinson Disease | Phase 2 | Status: TERMINATED